manufactured by Eurofins BPT FI Oy according to the design of the commercial product will be used. clinical trials

Prospective, randomized, double-blind, placebo-controlled, single-center comparative trial evaluating oral hydroxychloroquine 200 mg BID for reducing microglial activation in the brain of patients with progressive multiple sclerosis (MS)

This study is testing if a drug called hydroxychloroquine can help slow down multiple sclerosis (MS) in people with progressive forms of the disease. Researchers want to see if it reduces brain inflammation using special scans and also check if it improves walking, thinking, and daily life.